Phase II study to investigate efficacy and safety of erlotinib in patients with advanced and recurrent NSCLC with poor performance status - Phase II study to investigate efficacy and safety of erlotinib in patients with advanced and recurrent NSCLC with poor performance status

Yamaguchi Thoracic Oncology Group(YTOG)0 个研究点目标入组 20 人开始时间: 2010年4月30日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Patients with pulmonary disorders including idiopathic pulmonary fibrosis, interstitial lung disease, pneumoconiosis, active radiation pneumonia and drug-induced pneumonia (2) Massive pleural effusion, pericardial effusion, ascites, and superior vena cava syndrome (3)Patients with complication with infectious disease which requires intravenous injection of antibiotic or antimycotic agent (4) Patients who have been treated with HER drugs (gefitinib, trastuzumab, lapatinib, cetuximab) (5) Patients who are not able to take oral medication (6) Patients with clinically significant ophthalmologic disorder (severe eye disorders including Sjogren's syndrome, keratoconjunctivitis sicca, keratitis) (7) Pregnant or lactating women (8) Brain metastasis with symptoms (9) Active multiple cancer (10) Diabetes patients with poor disease control (11) Patients with clinically significant complications (including cardiac disorder with poor control, severe arrhythmia requires medication, persistent watery diarrhea) (12) Patients who are considered ineligible based on decision of a responsible investigator

发起方

Yamaguchi Thoracic Oncology Group(YTOG)